Commentary Open Access
Volume 2 | Issue 4 | DOI: https://doi.org/10.33696/diabetes.1.028

Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?

  • 1Center for Neural Science and Medicine, Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Department of Neurology, Cedars-Sinai Medical Center, 127 South San Vicente Boulevard, Los Angeles CA 90048, USA
  • 2David Geffen School of Medicine, University of California, Los Angeles, USA
+ Affiliations - Affiliations

Corresponding Author

Celine E Riera, Celine.riera@cshs.org

Received Date: November 20, 2020

Accepted Date: December 29, 2020

Author Information X